Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Cel-Sci
AddedFeb 19, 2024
UpdatedJun 18, 2026
Cel-Sci

Cel-Sci

Public

CEL-SCI: A US-based biotech firm innovating immunotherapy solutions for cancer and infectious diseases.

HQ
Vienna, VA, US
Founded
1983
Overview
Compare
Fundraising
Employees
Website

Founded in Vienna, United States, CEL-SCI is a biotechnology company focused on developing innovative immunotherapy products for cancer and infectious diseases. The company's core mission is to improve the treatment of cancer, autoimmune, and infectious diseases through advanced research and development. CEL-SCI's flagship product, Multikine, is an immunotherapy treatment designed to enhance the body's natural immune response against tumors. The company targets the oncology market and aims to provide effective therapeutic solutions that can significantly improve patient outcomes.

CEL-SCI has garnered attention through notable affiliations with leading research institutions and investors in the biotech industry. Key achievements include FDA approval for clinical trials of Multikine and significant findings presented at major conferences such as ASCO, ESMO, and ECHNO. The company's pioneering work in immunotherapy has positioned it as a significant player in the biotech sector, contributing to advancements in cancer treatment and offering hope for patients with limited options.

Cel-Sci - Similar Companies

Imunon logo

Imunon

imunon.com

Celldex Therapeutics logo

Celldex Therapeutics

Immunome logo

Immunome

Nantkwest logo

Nantkwest

Celularity logo

Celularity

celularity.com

Cellerant Therapeutics logo

Cellerant Therapeutics

Iovance Biotherapeutics logo

Iovance Biotherapeutics

iovance.com

ImmunityBio logo

ImmunityBio

immunitybio.com

Cleveland BioLabs logo

Cleveland BioLabs

Cell BioEngines logo

Cell BioEngines

cellbioengines.com

Lyell Immunopharma logo

Lyell Immunopharma

lyell.com

Bellicum Pharmaceuticals logo

Bellicum Pharmaceuticals

MacroGenics logo

MacroGenics

macrogenics.com

Cellular Approaches logo

Cellular Approaches

Targazyme logo

Targazyme

targazyme.com

Cel-Sci - Quick Facts

Who are Cel-Sci's competitors?

Companies similar to Cel-Sci include Imunon, Celldex Therapeutics, Immunome and Nantkwest.

When was Cel-Sci founded?

Cel-Sci was founded in 1983.

Where is Cel-Sci's headquarters located?

Cel-Sci's headquarters is located in Vienna, VA, US.

When was Cel-Sci's last funding round?

Cel-Sci's most recent funding round was for $5M (USD) in November 2023.

How much has Cel-Sci raised to-date?

As of Nov 15, 2023, Cel-Sci has raised a total of $67.4M (USD).

How many employees does Cel-Sci have?

Cel-Sci has 44 employees as of Feb 6, 2024.

Cel-Sci - Classification

Ownership
  • Public
Technology
  • Biotech
Geographic Exposure
  • United States
Revenue
  • Recurring
Customer
  • Enterprise
Main Product
  • Cancer Treatment
  • Immunotherapy
Tags
  • Biotech
  • Healthtech
Unique IDs
  • ein: 840916344
  • secCik: 0000725363
  • ticker: CVM
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 541000Professional, Scientific, and Technical Services
  • 541700Scientific Research and Development Services
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 2836Biological Products, Except Diagnostic Substances
  • 2800Chemicals And Allied Products
  • 2830Drugs
ISIC
  • 2100Manufacture of pharmaceuticals, medicinal chemical and botanical products
Show 19 more industry codes
NAICS
  • 320000Manufacturing
  • 325400Pharmaceutical and Medicine Manufacturing
  • 325414Biological Product (except Diagnostic) Manufacturing
  • 620000Health Care and Social Assistance
  • 325000Chemical Manufacturing
  • 623000Nursing and Residential Care Facilities
  • 325410Pharmaceutical and Medicine Manufacturing
  • 325412Pharmaceutical Preparation Manufacturing
  • 541715Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SIC
  • 8733Noncommercial Research Organizations
  • 4000Railroad Transportation
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 2834Pharmaceutical Preparations
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research
ISIC
  • 7210Research and experimental development on natural sciences and engineering